Welcome to our dedicated page for PACS Group SEC filings (Ticker: PACS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PACS Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PACS Group's regulatory disclosures and financial reporting.
PACS reported insider sales by Mark Hancock via a Form 144 filing: 153,254 shares sold on 06/15/2026, 83,066 shares sold on 06/16/2026, and 63,680 shares sold on 06/17/2026. The transactions are listed as Common stock dispositions with cash consideration.
PACS submitted a Form 144 notice listing proposed sales of Common Stock through J.P. Morgan Securities LLC. The filing lists a proposed sale quantity of 45,000 shares, a beneficially held figure of 1,748,250 shares, and a total share count of 158,272,376 with an effective date of 06/25/2026. The notice also identifies RSU vesting-related shares of 31,616 (04/15/2026) and 13,384 (04/15/2025) shown as compensation.
PACS Group, Inc. director and executive vice chair Mark Hancock reported two open-market sales of common stock on June 17, 2026 totaling 63,680 shares. The shares were sold at weighted average prices of $35.2838 and $35.7491 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. After these transactions, Hancock directly holds about 54.3 million shares of PACS Group common stock.
PACS filing a Form 144 reporting proposed sales by an insider. The filing lists two sale notices by Mark Hancock totaling 236,320 shares sold on 06/15/2026 ($5,568,759.95) and 06/16/2026 ($2,982,385.05), respectively. The record shows securities originally acquired at formation on 03/01/2023 and an aggregate holding line of 54,626,199 shares as of 03/01/2023. The broker-dealer listed is Citigroup Global Markets Inc on the NYSE.
PACS Group, Inc. director and co-founder Mark Hancock reported open-market sales of company common stock. Across four transactions on June 15–16, 2026, he sold a total of 236,320 shares, including 83,066 shares at a weighted average price of $35.9038 per share and 134,093 shares at $36.2341 per share.
The filing states these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026, indicating they were scheduled in advance. After these transactions, Hancock directly owned 54,366,277 shares of PACS Group common stock.
Mark Hancock reports a Rule 144 sale of 153,254 shares of Common Stock. The filing records a trade date of 06/15/2026 and proceeds of $5,568,759.95. The notice names Citigroup Global Markets Inc and also shows 54,626,199 shares acquired at formation on 03/01/2023 as background information.
PACS Group, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. A total of 152,966,362 shares of common stock were represented online or by proxy, representing approximately 97.33% of shares outstanding as of the April 15, 2026 record date, indicating very high stockholder participation.
Stockholders elected Class II directors Evelyn Dilsaver and Mark Hancock to serve until the 2029 Annual Meeting. Dilsaver received 138,610,797 votes for and 7,339,538 votes withheld, while Hancock received 145,054,309 votes for and 896,026 votes withheld, with 7,016,027 broker non-votes for each nominee.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 152,909,016 votes for, 46,759 against, and 10,587 abstaining. In addition, they approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 131,950,911 votes for, 13,973,853 against, 25,571 abstentions, and 7,016,027 broker non-votes.
PACS Group, Inc. director Patrick Hugh Conway received a grant of 4,660 restricted stock units (RSUs) of Common Stock. These RSUs convert into one share each upon vesting, giving him 8,157 shares in total after the award. All RSUs vest 100% on the earlier of June 10, 2027 or the next annual meeting following the grant date, as long as he continues serving the company.
LEAVITT TAYLOR S. reported acquisition or exercise transactions in this Form 4 filing.
PACS Group, Inc. director Taylor S. Leavitt received an equity grant of 4,660 restricted stock units (RSUs), each convertible into one share of common stock upon vesting. After this award, Leavitt holds 15,497 shares of common stock directly.
The RSUs will vest 100% on the earlier of June 10, 2027 or the date of the next annual meeting following the grant, as long as Leavitt continues to serve the company. This filing reflects a compensation-related share award rather than an open-market purchase or sale.